(no title)
profunctor | 1 year ago
Interesting article. I have to say I was shocked at the lack of evidence re puberty blockers. I was not shocked that the nhs was trying to hide any true measurements of the effectiveness of its treatments.
At the end of the day we all want kids to have a good, happy life. If puberty blockers are not some easily reversible intervention with few side effects then maybe we should not give them out. Although I’m not sure that it has been proven to be harmful, more research needed?
I am a bit conflicted with the authors opinion that we should not offer full medical transition to adults. I mostly believe adults should be able to do as they wish if they are not hurting anyone (seemingly in accordance with the authors liberal ideology). But we all have to agree that at 18 we were not always capable of making the right decisions for us. I know trans people who transitioned in their late 20s and they are the most happy they have ever been.
Thankfully we have true scientists happy to do the hard yards of creating reports like the one described. Brave and difficult work.
gresl|1 year ago
The systematic review commissioned by Cass on the outcomes of puberty blocking interventions is here: https://doi.org/10.1136/archdischild-2023-326669
The authors' quality assessment of each study is here: https://adc.bmj.com/content/archdischild/early/2024/04/09/ar...
Of the 50 studies in that list, which of these do you suspect were excluded for dubious reasons?
strangecasts|1 year ago
To be precise, the report excluded studies of blockers for not being blinded, in a recreation of the 2003 review of parachute efficiacy [1]
Not that it's particularly consistent about any evidentiary standard, as they happily cite a "self-identified sample of 100 completing an anonymous online questionnaire" later on
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC300808/
gresl|1 year ago
No, studies were excluded for being of poor quality per their rating on the Newcastle-Ottawa Scale, which is a tool used to assess the quality of non-randomized studies.
You can see the review authors' scoring of each study here: https://adc.bmj.com/content/archdischild/early/2024/04/09/ar...
Those excluded have a NOS total score of 4 or less and, as this table shows, a score that low is for multiple reasons including not having a representative cohort and inadequacy of follow-up.
The review itself can be read here: https://adc.bmj.com/content/early/2024/04/09/archdischild-20...
profunctor|1 year ago